Patricia Brafford

6.4k total citations · 2 hit papers
24 papers, 3.5k citations indexed

About

Patricia Brafford is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Patricia Brafford has authored 24 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in Patricia Brafford's work include Melanoma and MAPK Pathways (8 papers), Cancer Cells and Metastasis (4 papers) and Epigenetics and DNA Methylation (3 papers). Patricia Brafford is often cited by papers focused on Melanoma and MAPK Pathways (8 papers), Cancer Cells and Metastasis (4 papers) and Epigenetics and DNA Methylation (3 papers). Patricia Brafford collaborates with scholars based in United States, Germany and Australia. Patricia Brafford's co-authors include Meenhard Herlyn, Keiran S.M. Smalley, Nikolas K. Haass, Susan E. Zabierowski, Mizuho Fukunaga‐Kalabis, Adina Vultur, Alexander Roesch, Phyllis A. Gimotty, Thomas Vogt and Devraj Basu and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Patricia Brafford

24 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

2010 872 citations Alexander Roesch, Mizuho Fukunaga‐Kalabis et al. Cell profile →
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

2017 756 citations Sydney M. Shaffer, Margaret C. Dunagin et al. Nature profile →

Peers

Countries citing papers authored by Patricia Brafford

Since Specialization

Citations

This map shows the geographic impact of Patricia Brafford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Brafford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Brafford more than expected).

Fields of papers citing papers by Patricia Brafford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Brafford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Brafford. The network helps show where Patricia Brafford may publish in the future.

Co-authorship network of co-authors of Patricia Brafford

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Brafford. A scholar is included among the top collaborators of Patricia Brafford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Brafford. Patricia Brafford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity 2024 ·Nature Communications ·(unknown), (unknown), Cecily C. Ritch, Hsin‐Yao Tang, Hongguang Shao, Harsh Dweep, (unknown), Rebekah Brooks, Patricia Brafford, Adam J. Wolpaw, Yool Lee, Ashani T. Weeraratna, Amita Sehgal, Meenhard Herlyn, Andrew V. Kossenkov, David W. Speicher, Peter K. Sorger, Sandro Santagata, Chi V. Dang	18
2	Na+/H+-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells 2022 ·Cancer Research Communications ·(unknown), Hongguang Shao, (unknown), Patricia Brafford, Zachary E. Stine, Jing Sun, Dean W. Felsher, Jordan S. Orange, Steven Μ. Albelda, Chi V. Dang	1
3	Epigenetic state determines inflammatory sensing in neuroblastoma 2022 ·Proceedings of the National Academy of Sciences ·Adam J. Wolpaw, (unknown), (unknown), (unknown), (unknown), Patricia Brafford, (unknown), Guillem Pascual‐Pasto, Alba Rodríguez-García, Yasin Uzun, Marie Arsenian‐Henriksson, Daniel J. Powell, Kristopher R. Bosse, Andrew V. Kossenkov, Kai Tan, Michael D. Hogarty, John M. Maris, Chi V. Dang	28
4	Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma 2021 ·Oncogene ·(unknown), Bénédicte Haenig, (unknown), (unknown), (unknown), Richard W.D. Welford, (unknown), (unknown), Clemens Krepler, Patricia Brafford, Min Xiao, Meenhard Herlyn, Matthias Gstaiger, François Lehembre, (unknown)	8
5	Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance breakdown → 2017 ·Nature ·Sydney M. Shaffer, Margaret C. Dunagin, Stefan Torborg, Eduardo A. Torre, Benjamin Emert, Clemens Krepler, Marilda Beqiri, Katrin Sproesser, Patricia Brafford, Min Xiao, (unknown), Ioannis N. Anastopoulos, Cesar A. Vargas-García, Abhyudai Singh, Katherine L. Nathanson, Meenhard Herlyn, Arjun Raj	756
6	Distinct histone modifications denote early stress-induced drug tolerance in cancer 2017 ·Oncotarget ·Abdullah Al Emran, Diego M. Marzese, Dinoop Ravindran Menon, Mitchell Stark, (unknown), Heinz Hammerlindl, Gao Zhang, Patricia Brafford, Matthew P. Salomon, Nellie Nelson, (unknown), (unknown), Gordon B. Mills, Yiling Lu, Richard A. Sturm, Keith T. Flaherty, Dave S.�B. Hoon, Brian Gabrielli, Meenhard Herlyn, Helmut Schaider	57
7	Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma 2016 ·Molecular Cancer Research ·Nail Fatkhutdinov, Katrin Sproesser, Clemens Krepler, Qin Liu, Patricia Brafford, Meenhard Herlyn, Katherine M. Aird, Rugang Zhang	23
8	1205Lu is Human Melanoma Depending on the Source 2016 ·Journal of Cancer Science & Therapy ·Patricia Brafford, Katrin Sproesser	2
9	MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer 2015 ·Clinical Cancer Research ·(unknown), Philip C. Miller, Dorraya El‐Ashry, Jun Sun, Alexandra H. Besser, Tan A. Ince, Mengnan Gu, Zhi Wei, Gao Zhang, Patricia Brafford, Wei Gao, Yiling Lu, Gordon B. Mills, Joyce M. Slingerland, Fiona Simpkins	46
10	A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth breakdown → 2010 ·Cell ·Alexander Roesch, Mizuho Fukunaga‐Kalabis, (unknown), Susan E. Zabierowski, Patricia Brafford, Adina Vultur, Devraj Basu, Phyllis A. Gimotty, Thomas Vogt, Meenhard Herlyn	872
11	PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas 2010 ·Pigment Cell & Melanoma Research ·John Tayu Lee, Ling Li, Patricia Brafford, (unknown), Molly B. Halloran, Katrin Sproesser, Nikolas K. Haass, Keiran S.M. Smalley, James Tsai, Gideon Bollag, Meenhard Herlyn	124
12	Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes 2009 ·Cancer Research ·Chelsea C. Pinnix, John Tayu Lee, Zhaojun Liu, (unknown), Klara Balint, Levi J. Beverly, Patricia Brafford, Min Xiao, Benjamin Himes, Susan E. Zabierowski, Yumi Yashiro–Ohtani, Katherine L. Nathanson, (unknown), Pamela M. Pollock, Ashani T. Weeraratna, Brian J. Nickoloff, Warren S. Pear, Anthony J. Capobianco, Meenhard Herlyn	94
13	Dysregulation of Claudin-7 Leads to Loss of E-Cadherin Expression and the Increased Invasion of Esophageal Squamous Cell Carcinoma Cells 2007 ·American Journal Of Pathology ·Mercedes Lioni, Patricia Brafford, Claudia D. Andl, Anil K. Rustgi, Wafik S. El‐Deiry, Meenhard Herlyn, Keiran S.M. Smalley	115
14	Mutant V600E BRAF Increases Hypoxia Inducible Factor-1α Expression in Melanoma 2007 ·Cancer Research ·Suresh Kumar, Hong Yu, Robin Edwards, Lianjun Chen, Steven Kazianis, Patricia Brafford, Géza Ács, Meenhard Herlyn, Xiaowei Xu	116
15	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases 2006 ·Molecular Cancer Therapeutics ·Keiran S.M. Smalley, Nikolas K. Haass, Patricia Brafford, Mercedes Lioni, Keith T. Flaherty, Meenhard Herlyn	370
16	Defining the Conditions for the Generation of Melanocytes from Human Embryonic Stem Cells 2006 ·Stem Cells ·Dong Fang, (unknown), Thiennga K. Nguyen, (unknown), Kun Cai, Mizuho Fukunaga, Ling Li, Patricia Brafford, Angela N. Kulp, Xiaowei Xu, Keiran S.M. Smalley, Meenhard Herlyn	88
17	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature 2006 ·Pigment Cell Research ·Keith S. Hoek, Natalie C. Schlegel, Patricia Brafford, Antje Sucker, Selma Ugurel, Rajiv Kumar, Barbara L. Weber, Katherine L. Nathanson, David J. Phillips, Meenhard Herlyn, Dirk Schadendorf, Reinhard Dummer	410
18	Selective evolutionary pressure from the tissue microenvironment drives tumor progression 2005 ·Seminars in Cancer Biology ·Keiran S.M. Smalley, Patricia Brafford, Meenhard Herlyn	39
19	Up-Regulated Expression of Zonula Occludens Protein-1 in Human Melanoma Associates with N-Cadherin and Contributes to Invasion and Adhesion 2005 ·American Journal Of Pathology ·Keiran S.M. Smalley, Patricia Brafford, Nikolas K. Haass, Johanna M. Brandner, Eric J. Brown, Meenhard Herlyn	123
20	Differential expression of connexins in melanoma and adjacent epidermis 2004 ·Cancer Research ·Nikolas K. Haass, Johanna M. Brandner, Patricia Brafford, Ewa Wladykowski, Steven Kazianis, Keiran S.M. Smalley, Ingrid Moll, Meenhard Herlyn	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact